HCSG
Healthcare Services Group, Inc.
HCSG has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
HCSG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
HCSG's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HCSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.02 | — |
| Cheap | 19x | $28.51 | +14% |
| Forward | 21x | $25.02 | — |
| Fair | 24x | $35.09 | +40% |
| Expensive | 35x | $52.32 | +109% |
Historical ranges are pointers, not guarantees.
HCSG's PE is in its cheap range at 17x. On analysts' estimates for next year's earnings, today's price would be 21x.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over HCSG in the historical PE scenario, which offers more potential upside but is not a forecast.
HCSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
HCSG has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HCSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.18 | -20% |
| Q3 2026 | $1.48 | +179% |
| Q2 2026 | $1.71 | +1215% |
| Q1 2026 | $0.95 | +73% |
| Q4 2025 | $0.81 | +53% |
| Q3 2025 | $0.53 | -22% |
| Q2 2025 | $0.13 | -69% |
| Q1 2025 | $0.55 | -1.8% |
| Q4 2024 | $0.53 | +1.9% |
HCSG earned $1.48 per share over the past year, up 179% from the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
HCSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $479.6M | +3.3% |
| Q2 2026 | $470.8M | +2.7% |
| Q1 2026 | $462.8M | +3.4% |
| Q4 2025 | $466.7M | +6.6% |
| Q3 2025 | $464.3M | +8.5% |
| Q2 2025 | $458.5M | +7.6% |
| Q1 2025 | $447.7M | +5.7% |
| Q4 2024 | $437.8M | +3.3% |
HCSG's revenue has grown year over year for 11 quarters in a row: $480M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | -5.3 points |
| Q2 2026 | 6.6% | +16 points |
| Q1 2026 | 7.5% | +2.1 points |
| Q4 2025 | 6.1% | +2.7 points |
| Q3 2025 | 12% | +8 points |
| Q2 2025 | -9.1% | -8.7 points |
| Q1 2025 | 5.3% | +0.3 points |
| Q4 2024 | 3.4% | -3.9 points |
HCSG's operating margin was 7% last quarter, down 5.3 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over HCSG on profitability, with a higher operating margin.
HCSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.1M | -60% |
| Q2 2026 | $20.2M | -26% |
| Q1 2026 | $42.3M | +64% |
| Q4 2025 | $16M | -54% |
| Q3 2025 | $70M | +2302% |
| Q2 2025 | $27.4M | +83% |
| Q1 2025 | $25.8M | +$54M |
| Q4 2024 | $34.8M | -28% |
HCSG still generates free cash flow, though less than at its 2020 peak: $107M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over HCSG on cash flow, with more consistent year-over-year improvement.
HCSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -526K shares |
| 1 year | -4.9% | -3.6M shares |
| 3 years | -6.7% | -5M shares |
| 5 years | -7.6% | -5.7M shares |
| Available history | -7% | -5.2M shares |
HCSG has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11.7M |
| Q2 2026 | $20.9M |
| Q1 2026 | $24M |
| Q4 2025 | $19.6M |
| Q3 2025 | $27.3M |
| Q2 2025 | $7.7M |
| Q1 2025 | $7M |
| Q4 2024 | $1M |
HCSG spent $76M buying back its own shares over the past year, up 77% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
HCSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -1.4x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -2.6x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
HCSG has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
HCSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 70.5 | Neutral |
HCSG's weekly RSI is 61 (neutral) and its Stochastic is 71 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HCSG PE vs Healthcare Sector
| Metric | HCSG | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 35% below |
| PE % | 6 | 29 | 23 pts below |
HCSG is trading at 17x earnings, a 35% discount to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over HCSG on valuation relative to its sector.
HCSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.9 | 9.5% above |
| 20 week MA | $22.9 | 9.4% above |
| 50 week MA | $21.3 | 17% above |
| 100 week MA | $17.5 | 43% above |
| 200 week MA | $14.7 | 71% above |
HCSG has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
HCSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.3 | $27.1 | +11% |
| 2021 | $27.1 | $17.2 | -37% |
| 2022 | $17.2 | $12.2 | -29% |
| 2023 | $12.2 | $10.4 | -15% |
| 2024 | $10.4 | $11.5 | +11% |
| 2025 | $11.5 | $19.6 | +70% |
| 2026 YTD | $19.6 | $25.0 | +27% |
HCSG has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.